Deferiprone in iron overload Journal Article
| Author: | Adhikari, D. |
| Article Title: | Deferiprone in iron overload |
| Abstract: | To the Editor: Olivieri et al. (April 6 issue)1 are to be congratulated on their work on deferiprone, which, in addition to demonstrating the drug's efficacy in iron chelation, is the only study so far to have addressed some of the controversies surrounding the use of the drug.2–5 Our experience with autoimmune phenomena has not been confined to just one case of fatal drug-induced systemic lupus erythematosus.2 We have found a significantly higher incidence of antinuclear antibodies in patients with thalassemia treated with deferiprone (7 of 27) than in those not receiving the drug (2 of 63, P<0.01). Antibodies. © 1995, Massachusetts Medical Society. All rights reserved. |
| Keywords: | clinical trial; neutropenia; drug efficacy; letter; nephrotoxicity; gastrointestinal symptom; nausea; chemistry, pharmaceutical; pyridones; time factors; thalassemia; antinuclear antibody; zinc deficiency; histones; autoantibodies; deferoxamine; bone marrow toxicity; arthropathy; oral drug administration; iron chelation; iron chelating agents; iron overload; agranulocytosis; iron storage; deferiprone; human; priority journal; antibodies, antinuclear; orphan drug; histone antibody; deferriferrithiocin |
| Journal Title: | New England Journal of Medicine |
| Volume: | 333 |
| Issue: | 9 |
| ISSN: | 0028-4793 |
| Publisher: | Massachusetts Medical Society |
| Date Published: | 1995-08-31 |
| Start Page: | 598 |
| Language: | English |
| DOI: | 10.1056/nejm199508313330915 |
| PUBMED: | 7623917 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Letter -- Export Date: 28 August 2018 -- Source: Scopus |
